胃癌手术后替吉奥单药口服化疗的临床疗效

摘要

Objective:To observe clinical application and results of patients with operable gastric cancer treated with S-1 monotherapy. Methods:Clinical stage Ⅱ and Ⅲ patients with gastric cancer,and after surgery to get healed were selected as objects,the test group was given S-1 after one month,with dosage of 80mg/(m2·d),divid-ed doses in morning and night,day 1-14 medication;Control group was given standard regimen:FOLFOX4,every two weeks as a period. Finally,two groups were evaluated after 3 cycles. Results:In two groups,incidence of adverse reac-tions,KPS score level,clinical benefit rate,efficient rate,2-year survival rate of patients after surgery,were no signif-icant statistical difference. Conclusion:For gastric cancer patients after surgery with S-1 single drug treatment,ad-verse reactions are mild,and there were no significant difference between the test group and the control group on 2-year survival rate,and treatment compliance.%目的：观察可手术的胃癌患者术后替吉奥单药的临床应用及其效果。方法：以临床分期Ⅱ期及Ⅲ期胃癌患者，并经手术治疗后获得痊愈者为入选对象，术后1个月试验组给予替吉奥胶囊口服，用量为80mg/（ m2·d），早晚分次口服，d1-14。对照组给于FOLFOX4标准方案，每2周作为一个周期，3周期后评价疗效。结果：试验组与对照组比较：在不良反应发生率、KPS评分级别、临床获益率、有效率、患者手术后2年生存率均无明显统计学差异。结论：胃癌手术后应用替吉奥单药控制，不良反应轻微，术后2年生存率与对照组相比无统计学差异，治疗依从性较好，值得推广应用。